A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old.

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

A protein linked to aggressive bladder cancers could point to new strategies for treatment or prevention.

Targeting immune system proteins may keep prostate cancer from spreading to bone.

Vanderbilt researchers have been selected to receive a national grant as part of a push to gauge the coming impact of the Affordable Care Act (ACA).

As more and better treatments are developed for heart disease, it is becoming more difficult to safely manage care as patients return home from the hospital. A new study led by Vanderbilt researchers highlights growing concern that the period after hospital discharge is a risky time, especially for cardiac patients.